Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Redwan Farooq

MB BChir MA (Cantab) DPhil (Oxon) MRCP


Clinical Research Fellow

  • Postdoctoral Researcher
  • Specialty Registrar in Neurology

I am a clinician with an interest in neuroinflammatory diseases, especially multiple sclerosis (MS), and computational biology.

After obtaining my primary medical degree with an intercalated BA in Neuroscience from the University of Cambridge, I completed several years of postgraduate clinical training in various London teaching hospitals with specialty training in Neurology.

I was awarded a Clinical Research Training Fellowship, jointly funded by the Association of British Neurologists and Guarantors of Brain, to complete a DPhil at the University of Oxford, working within the Oxford Centre for Neuroinflammation.

My doctoral research leveraged high-efficacy MS therapies as perturbational probes to characterise pathogenic immune interactions across disease stages and tissue compartments, using samples from people with MS. To effectively isolate conserved treatment effects from inter-donor heterogeneity and technical noise, I developed a bespoke computational analytical pipeline for in vivo drug perturbation analysis using longitudinal single-cell data from clinical cohorts.

Using this approach, I identified a distinct chronically activated, proinflammatory–cytotoxic, tissue-homing, and residency-primed memory T cell state, plausibly linked to chronic latent EBV infection in memory B cells, and integrated these findings into a model of a pathogenic B–T cell axis in MS. This model may bridge peripheral immune activation to the chronic, compartmentalised CNS inflammation responsible for treatment-resistant, relapse-independent disability progression, offering new implications for future therapeutic strategies.

I am now advancing this work as a postdoctoral researcher while completing my final year of specialty training.